{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:47:01Z","timestamp":1790797621136,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19-AI171954"],"award-info":[{"award-number":["U19-AI171954"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["slas-discovery.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["SLAS Discovery"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.slasd.2024.100181","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T10:23:17Z","timestamp":1724408597000},"page":"100181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["SARS-CoV-2 Mpro inhibitor identification using a cellular gain-of-signal assay for high-throughput screening"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7148-4917","authenticated-orcid":false,"given":"Renee","family":"Delgado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Vishwakarma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6598-8994","authenticated-orcid":false,"given":"Seyed Arad","family":"Moghadasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3739-5790","authenticated-orcid":false,"given":"Yuka","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2799-9611","authenticated-orcid":false,"given":"Justin","family":"Shumate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Cuell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1375-7722","authenticated-orcid":false,"given":"Megan","family":"Tansiongco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9699-7682","authenticated-orcid":false,"given":"Christina B.","family":"Cooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1499-4950","authenticated-orcid":false,"given":"Agnieszka","family":"Dabrowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7048-4017","authenticated-orcid":false,"given":"Rahul","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina Duhita","family":"Anindita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7637-7275","authenticated-orcid":false,"given":"Dahai","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0081-3867","authenticated-orcid":false,"given":"Peter I.","family":"Dosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5950-931X","authenticated-orcid":false,"given":"Daniel A.","family":"Harki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0683-8886","authenticated-orcid":false,"given":"Thomas","family":"Bannister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7734-0105","authenticated-orcid":false,"given":"Louis","family":"Scampavia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Spicer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9034-9112","authenticated-orcid":false,"given":"Reuben S.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.slasd.2024.100181_bib0001","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6660930","article-title":"A Systematic review and meta-analysis of risk factors associated with severity and death in COVID-19 patients","author":"Du","year":"2021","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"10.1016\/j.slasd.2024.100181_bib0002","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s10654-021-00787-9","article-title":"Over- and under-estimation of COVID-19 deaths","volume":"36","author":"Ioannidis","year":"2021","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.slasd.2024.100181_bib0003","doi-asserted-by":"crossref","first-page":"o1144","DOI":"10.1136\/bmj.o1144","article-title":"Covid-19: true global death toll from pandemic is almost 15 million, says WHO","volume":"377","author":"Taylor","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.slasd.2024.100181_bib0004","doi-asserted-by":"crossref","first-page":"e37502","DOI":"10.1097\/MD.0000000000037502","article-title":"Long COVID's impact on patients, workers, & society: a review","volume":"103","author":"Kavanagh","year":"2024","journal-title":"Medicine"},{"key":"10.1016\/j.slasd.2024.100181_bib0005","doi-asserted-by":"crossref","first-page":"bvae043","DOI":"10.1210\/jendso\/bvae043","article-title":"Long covid: hormone imbalances and\/or rather complex immune dysregulations?","volume":"8","author":"Koch","year":"2024","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.slasd.2024.100181_bib0006","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jinf.2023.01.024","article-title":"Characteristics and risk factors of prolonged viable virus shedding in immunocompromised patients with COVID-19: a prospective cohort study","volume":"86","author":"Kang","year":"2023","journal-title":"J Infect"},{"key":"10.1016\/j.slasd.2024.100181_bib0007","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/cid\/ciaa863","article-title":"COVID-19 in immunocompromised hosts: what we know so far","volume":"72","author":"Fung","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.slasd.2024.100181_bib0008","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.1002\/mco2.307","article-title":"Risk and outcomes of breakthrough COVID-19 infections in vaccinated immunocompromised patients: a meta-analysis","volume":"4","author":"Deng","year":"2023","journal-title":"MedComm"},{"key":"10.1016\/j.slasd.2024.100181_bib0009","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1093\/infdis\/jiad181","article-title":"The burden of COVID-19 in the immunocompromised patient: implications for vaccination and needs for the future","volume":"228","author":"Antinori","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.slasd.2024.100181_bib0010","article-title":"Pharmacokinetic analysis of placental transfer of ritonavir as a component of paxlovid using microdialysis in pregnant rats","volume":"10","author":"Sun","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.slasd.2024.100181_bib0011","doi-asserted-by":"crossref","DOI":"10.3390\/v15030704","article-title":"Use of oral antivirals ritonavir-nirmatrelvir and molnupiravir in patients with multiple myeloma is associated with low rates of severe COVID-19: a single-Center, prospective study","volume":"15","author":"Spiliopoulou","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.slasd.2024.100181_bib0012","first-page":"1","article-title":"Safety and efficacy of Paxlovid in the treatment of adults with mild to moderate COVID-19 during the omicron epidemic: a multicentre study from China","author":"Li","year":"2024","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.slasd.2024.100181_bib0013","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16020217","article-title":"The design, synthesis and mechanism of action of paxlovid, a protease inhibitor drug combination for the treatment of COVID-19","volume":"16","author":"Bege","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.slasd.2024.100181_bib0014","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.54991","article-title":"Efficacy and safety of 5-day oral ensitrelvir for patients with mild to moderate COVID-19: the SCORPIO-SR randomized clinical trial","volume":"7","author":"Yotsuyanagi","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.slasd.2024.100181_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115503","article-title":"Bench-to-bedside: innovation of small molecule anti-SARS-CoV-2 drugs in China","volume":"257","author":"Yang","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.slasd.2024.100181_bib0016","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00697-22","article-title":"A Randomized Phase 2\/3 Study of ensitrelvir, a novel oral SARS-CoV-2 3C-like protease inhibitor, in japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection","volume":"66","author":"Mukae","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.slasd.2024.100181_bib0017","article-title":"Clinical development of antivirals against SARS-CoV-2 and its variants","volume":"6","author":"Lan","year":"2024","journal-title":"Curr Res Microb Sci"},{"key":"10.1016\/j.slasd.2024.100181_bib0018","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/17460441.2023.2267001","article-title":"Lessons learnt from the preclinical discovery and development of ensitrelvir as a COVID-19 therapeutic option","volume":"19","author":"Ferraro","year":"2024","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.slasd.2024.100181_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2024.105814","article-title":"Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains","volume":"222","author":"Bouzidi","year":"2024","journal-title":"Antiviral Res"},{"key":"10.1016\/j.slasd.2024.100181_bib0020","doi-asserted-by":"crossref","DOI":"10.3390\/v13050839","article-title":"HIV protease: historical perspective and current research","volume":"13","author":"Weber","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.slasd.2024.100181_bib0021","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1021\/acs.chemrev.0c00648","article-title":"Drug design strategies to avoid resistance in direct-acting antivirals and beyond","volume":"121","author":"Matthew","year":"2021","journal-title":"Chem Rev"},{"key":"10.1016\/j.slasd.2024.100181_bib0022","doi-asserted-by":"crossref","first-page":"11762","DOI":"10.1039\/D2CC04541A","article-title":"Beyond darunavir: recent development of next generation HIV-1 protease inhibitors to combat drug resistance","volume":"58","author":"Ghosh","year":"2022","journal-title":"Chem Commun"},{"key":"10.1016\/j.slasd.2024.100181_bib0023","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.3390\/v2112509","article-title":"Molecular basis for drug resistance in HIV-1 protease","volume":"2","author":"Ali","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.slasd.2024.100181_bib0024","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.vaccine.2023.02.032","article-title":"A research and development (R&D) roadmap for broadly protective coronavirus vaccines: a pandemic preparedness strategy","volume":"41","author":"Moore","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.slasd.2024.100181_bib0025","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","article-title":"Therapeutic strategies for COVID-19: progress and lessons learned","volume":"22","author":"Li","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.slasd.2024.100181_bib0026","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41423-023-01116-8","article-title":"In search of a pan-coronavirus vaccine: next-generation vaccine design and immune mechanisms","volume":"21","author":"Cankat","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.slasd.2024.100181_bib0027","article-title":"Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance","volume":"91","author":"Daniel","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.slasd.2024.100181_bib0028","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00872-20","article-title":"Discovery of M protease inhibitors encoded by SARS-CoV-2","volume":"64","author":"Hung","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.slasd.2024.100181_bib0029","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41422-020-0356-z","article-title":"Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease","volume":"30","author":"Ma","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.slasd.2024.100181_bib0030","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.00784-22","article-title":"Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 M(pro)\/3CL(pro) in Living Cells","volume":"13","author":"Moghadasi","year":"2022","journal-title":"mBio"},{"key":"10.1016\/j.slasd.2024.100181_bib0031","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/22221751.2021.1899770","article-title":"The preclinical inhibitor GS441524 in combination with GC376 efficaciously inhibited the proliferation of SARS-CoV-2 in the mouse respiratory tract","volume":"10","author":"Shi","year":"2021","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.slasd.2024.100181_bib0032","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1021\/acs.accounts.2c00735","article-title":"SARS-CoV-2 main protease drug design, assay development, and drug resistance studies","volume":"56","author":"Tan","year":"2023","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.slasd.2024.100181_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113584","article-title":"Improved SARS-CoV-2 Mpro inhibitors based on feline antiviral drug GC376: structural enhancements, increased solubility, and micellar studies","volume":"222","author":"Vuong","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.slasd.2024.100181_bib0034","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/s41586-023-06609-0","article-title":"Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir","volume":"622","author":"Duan","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.slasd.2024.100181_bib0035","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.bbrc.2004.04.098","article-title":"Characterization of SARS main protease and inhibitor assay using a fluorogenic substrate","volume":"318","author":"Kuo","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.slasd.2024.100181_bib0036","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s10529-011-0845-8","article-title":"Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in Pichia pastoris","volume":"34","author":"Nguyen","year":"2012","journal-title":"Biotechnol Lett"},{"key":"10.1016\/j.slasd.2024.100181_bib0037","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1021\/acs.jmedchem.9b01828","article-title":"\u03b1-ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment","volume":"63","author":"Zhang","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.slasd.2024.100181_bib0038","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1038\/s41467-020-18233-x","article-title":"Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease","volume":"11","author":"Fu","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.slasd.2024.100181_bib0039","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1021\/acs.jmedchem.1c00509","article-title":"Expedited approach toward the rational design of noncovalent SARS-CoV-2 main protease inhibitors","volume":"65","author":"Kitamura","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.slasd.2024.100181_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.852210","article-title":"Crystallization of feline coronavirus Mpro With GC376 reveals mechanism of inhibition","volume":"10","author":"Lu","year":"2022","journal-title":"Front Chem"},{"key":"10.1016\/j.slasd.2024.100181_bib0041","doi-asserted-by":"crossref","first-page":"11754","DOI":"10.1128\/JVI.01348-12","article-title":"Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses","volume":"86","author":"Kim","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.slasd.2024.100181_bib0042","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.virusres.2013.09.008","article-title":"Structural and inhibitor studies of norovirus 3C-like proteases","volume":"178","author":"Takahashi","year":"2013","journal-title":"Virus Res"},{"key":"10.1016\/j.slasd.2024.100181_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.103004","article-title":"Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease","volume":"299","author":"Noske","year":"2023","journal-title":"J Biol Chem"},{"key":"10.1016\/j.slasd.2024.100181_bib0044","doi-asserted-by":"crossref","first-page":"eade8778","DOI":"10.1126\/sciadv.ade8778","article-title":"Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors","volume":"9","author":"Moghadasi","year":"2023","journal-title":"Sci Adv"},{"key":"10.1016\/j.slasd.2024.100181_bib0045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s44259-023-00009-0","article-title":"Rapid resistance profiling of SARS-CoV-2 protease inhibitors","volume":"1","author":"Moghadasi","year":"2023","journal-title":"npj Antimicrob Resist"},{"key":"10.1016\/j.slasd.2024.100181_bib0046","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1021\/acscentsci.3c00538","article-title":"Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir","volume":"9","author":"Hu","year":"2023","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.slasd.2024.100181_bib0047","doi-asserted-by":"crossref","first-page":"7180","DOI":"10.1021\/acs.jcim.3c01269","article-title":"Discovery of nirmatrelvir resistance mutations in SARS-CoV-2 3CLpro: a computational-experimental approach","volume":"63","author":"Havranek","year":"2023","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.slasd.2024.100181_bib0048","doi-asserted-by":"crossref","first-page":"e29462","DOI":"10.1002\/jmv.29462","article-title":"Resistance-associated mutations to the anti-SARS-CoV-2 agent nirmatrelvir: selection not induction","volume":"96","author":"Colson","year":"2024","journal-title":"J Med Virol"},{"key":"10.1016\/j.slasd.2024.100181_bib0049","doi-asserted-by":"crossref","first-page":"e28441","DOI":"10.1002\/jmv.28441","article-title":"Efficacy and safety of nirmatrelvir\/ritonavir (Paxlovid) for COVID-19: a rapid review and meta-analysis","volume":"95","author":"Amani","year":"2023","journal-title":"J Med Virol"},{"key":"10.1016\/j.slasd.2024.100181_bib0050","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1038\/s41467-022-29915-z","article-title":"Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease","volume":"13","author":"Kneller","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.slasd.2024.100181_bib0051","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1021\/acsptsci.1c00099","article-title":"Rational design of hybrid SARS-CoV-2 main protease inhibitors guided by the superimposed cocrystal structures with the peptidomimetic inhibitors GC-376, telaprevir, and boceprevir","volume":"4","author":"Xia","year":"2021","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.slasd.2024.100181_bib0052","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009898","article-title":"Identification of novel modulators of a schistosome transient receptor potential channel targeted by praziquantel","volume":"15","author":"Chulkov","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.slasd.2024.100181_bib0053","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1177\/2472555218820809","article-title":"The Scripps Molecular Screening Center and Translational Research Institute","volume":"24","author":"Baillargeon","year":"2019","journal-title":"SLAS Discov"},{"key":"10.1016\/j.slasd.2024.100181_bib0054","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.slasd.2023.01.001","article-title":"High throughput screening for drugs that inhibit 3C-like protease in SARS-CoV-2","volume":"28","author":"Smith","year":"2023","journal-title":"SLAS Discov"},{"key":"10.1016\/j.slasd.2024.100181_bib0055","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1177\/2472555220963667","article-title":"High-throughput screening for drugs that inhibit papain-like protease in SARS-CoV-2","volume":"25","author":"Smith","year":"2020","journal-title":"SLAS Discov"},{"key":"10.1016\/j.slasd.2024.100181_bib0056","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/2472555220945283","article-title":"Identification of small-molecule inhibitors of neutral ceramidase (nCDase) via target-based high-throughput screening","volume":"26","author":"Otsuka","year":"2021","journal-title":"SLAS Discov"},{"key":"10.1016\/j.slasd.2024.100181_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.slasd.2024.100164","article-title":"A high throughput cell-based screening method for Zika virus protease inhibitors discovery","author":"Anindita","year":"2024","journal-title":"SLAS Discov"},{"key":"10.1016\/j.slasd.2024.100181_bib0058","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe0751","article-title":"Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M(pro) and cathepsin L","volume":"6","author":"Sacco","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.slasd.2024.100181_bib0059","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/07391102.2020.1813200","article-title":"Repurposing simeprevir, calpain inhibitor IV and a cathepsin F inhibitor against SARS-CoV-2 and insights into their interactions with Mpro","volume":"40","author":"Abhithaj","year":"2022","journal-title":"J Biomol Struct Dyn"},{"key":"10.1016\/j.slasd.2024.100181_bib0060","doi-asserted-by":"crossref","first-page":"16426","DOI":"10.1021\/acs.jmedchem.3c01876","article-title":"Design, synthesis, and biological evaluation of trisubstituted piperazine derivatives as noncovalent severe acute respiratory syndrome coronavirus 2 main protease inhibitors with improved antiviral activity and favorable druggability","volume":"66","author":"Gao","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.slasd.2024.100181_bib0061","doi-asserted-by":"crossref","first-page":"13343","DOI":"10.1021\/acs.jmedchem.2c01146","article-title":"Discovery and crystallographic studies of trisubstituted piperazine derivatives as non-covalent SARS-CoV-2 main protease inhibitors with high harget specificity and low toxicity","volume":"65","author":"Gao","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.slasd.2024.100181_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103579","article-title":"COVID-19 therapeutics: small-molecule drug development targeting SARS-CoV-2 main protease","volume":"28","author":"Kronenberger","year":"2023","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.slasd.2024.100181_bib0063","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202300301","article-title":"Conventional understanding of SARS-CoV-2 Mpro and common strategies for developing its inhibitors","volume":"24","author":"Zhou","year":"2023","journal-title":"Chembiochem"}],"container-title":["SLAS Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2472555224000431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2472555224000431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:11:11Z","timestamp":1726186271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2472555224000431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":63,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2472555224000431"],"URL":"https:\/\/doi.org\/10.1016\/j.slasd.2024.100181","relation":{},"ISSN":["2472-5552"],"issn-type":[{"value":"2472-5552","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SARS-CoV-2 Mpro inhibitor identification using a cellular gain-of-signal assay for high-throughput screening","name":"articletitle","label":"Article Title"},{"value":"SLAS Discovery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.slasd.2024.100181","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of Society for Laboratory Automation and Screening.","name":"copyright","label":"Copyright"}],"article-number":"100181"}}